AGL appears to be expanding its Parsortix liquid biopsy technology into brain cancer research, which could be a significant move. Given that brain tumors are difficult to biopsy surgically, a non-invasive liquid biopsy approach using cerebrospinal fluid (CSF) could be a game-changer. |
Thanks Gooosed for the links, much appreciated. |
Webinar :
"VIDEO | Complementary insights: Exploring the dual analysis of circulating tumour cells and circulating DNA"
On 06 February 2025, the EACR hosted a webinar in collaboration with Illumina, one of our valued EACR Industry Partners. We were delighted to welcome Anna Babayan, Senior Marketing Manager in Cancer Research at Illumina, and Anne-Sophie Pailhes-Jimenez who is the R&D Senior Director at ANGLE Europe Limited. In Anne-Sophie’s main presentation, she discussed how dual analysis of liquid biopsy analytes may hold potential to capture a more comprehensive picture of tumour heterogeneity and ultimately inform personalised cancer care.
Thanks to the speakers and Illumina, we are able to provide free on-demand access to the full webinar recording, which can be found above."
Personally I suspect most will find it better to watch via the undernoted YouTube link : |
Interesting presentation.
'Illumina are compensating me to speak at this event'
Just the start of Illumina sending cash Angle's way
[EDIT : Basically the whole thing was an advert for Angle PLC and Parsotix/CTC which Angle didn't have to pay for ! Illumina are really serious about developing this relationship. I will be shocked if they don't take AGL out lock,stock and barrel. The only negotiating point for AGL will be whether it is $20bn Illumina or $200bn AstraZeneca or $2Trillion Google/Apple/Microsoft etc who end up acquiring AGL] |
Here's the slides from Anne-Sophie's presentation yesterday :
The recording will be posted to the EACR YouTube channel in 7-10 days: |
price has more than doubled in a short space of time. Got to be profit taking by some and why not, Without further news this will likely drift a bit but the low volume/demand can be exploited. Watch those stops... |
Last director purchase was 2 years ago, they both bought at 27p a share. I still hold but will wait for more revenue news before I buy more. |
I would imagine insiders in closed period as there is so much market sensitive news they are aware of. Deals/Contracts |
Don't forget as well that the AZ deal was an extension of previous contract. Successful development of the AR assay is expected to bolster the use of the Parsortix system in clinical oncology, particularly for assessing the efficacy of prostate cancer therapies.The webinar yesterday eluded to prostate cancer tests. |
Maybe we are being lined up for a cheap takeover. No insiders buying even at the lows stops me from buying more. |
Well that’s no good I was waiting for the offer to drop to 14.5… |
Indeed. I wouldn't say AGL is a dead duck if AZN decide to walk away but it would certainly crater confidence and the share price if no other deals have been done to that point.
Thankfully though there are a few other irons in the fire now. |
Nigel,
I at the time drew the inference that the delay to announcing news on AZ was not indicative of a favourable outcome. Some suggested I was wrong to suggest there was a delay. We still do not know the eventual outcome (which in my view is critically important to Angle) although if one takes as reliable the alleged email from Angle then there is some hope of a positive outcome. |
I think you might have even suggested it was likely it had been terminated from memory Yasx - I'm not going to back through old posts though.
It's still a possibility that they will get to the end of their evaluation and walk away of course. |
I was right that AZ outcome is delayed - but at least it has not been terminated which was the issue of concern. |
That's helpful. I'd assumed that was the case but nice to have confirmed |
I received the below email for the finance director of Angle after asking IR about update on AstraZeneca. Expect news soon and good to know all going well.
Hi...
AZ did push the timeline out on the DDR work for internal scheduling purposes, but that and the other contracts are all progressing well. We will of course update the market when there are material changes.
Kind regards
Ian |
'Shake time'
Well overdue. |
Alsohttps://angleplc.com/webinars/ |
https://x.com/investwisely321/status/1887491515439620160/mediaViewer?currentTweet=1887491515439620160¤tTweetUser=investwisely321Have a look at this one...already posted,thanks earlier poster |
Anyone have a link to presentation ,thanks |
Will be interesting to see the number who listened in. Noted the illumina person suggested she'd answer illumina focused questions directly. Would be interested in her reply to a question on commercial implications. We need them though, as much as visa versa.we need the install base and fda approved labs in order to offer this for clinical use |
Yes Gooosed glad that was sneaked in at the end! |
Takeaway for me was - next up ctDNA, CTC & RNA analysis from one tube of blood. |
1000 samples means newsflow will increase Gives me great confidence in the partnership with Illumina. Good to see the clever people presenting and believing in the tech rather than the usual salesmanship |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
